Search Patents
  • FARS1, a human secreted protein and uses thereof
    Publication number: 20030113889
    Abstract: The invention provides isolated nucleic acids molecules, designated FARS1 nucleic acid molecules, which encode novel secreted proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing FARS1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a FARS1 gene has been introduced or disrupted. The invention still further provides isolated FARS1 proteins, fusion proteins, antigenic peptides and anti-FARS1 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 21, 2002
    Publication date: June 19, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ruth E. Gimeno, Mehran M. Khodadoust
  • 23686, a novel human aminotransferase and uses therefor
    Publication number: 20020107192
    Abstract: The invention provides isolated aminotransferase nucleic acids molecules, designated 23686 nucleic acid molecules, which encode novel 23686 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23686 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23686 gene has been introduced or disrupted. The invention still further provides isolated 23686 proteins, fusion proteins, antigenic peptides and anti-23686 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 25, 2001
    Publication date: August 8, 2002
    Inventor: Rory A.J. Curtis
  • 14790, Novel protein kinase molecule and uses therefor
    Publication number: 20020132321
    Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: February 29, 2000
    Publication date: September 19, 2002
    Inventors: William James Cook, Rosana Kapeller-Libermann
  • 57250, a novel human sugar transporter family member and uses thereof
    Publication number: 20020123094
    Abstract: The invention provides isolated nucleic acids molecules, designated HST-1 nucleic acid molecules, which encode novel sugar transporter family molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing HST-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an HST-1 gene has been introduced or disrupted. The invention still further provides isolated HST-1 polypeptides, fusion polypeptides, antigenic peptides and anti-HST-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: July 31, 2001
    Publication date: September 5, 2002
    Inventor: Rory A. J. Curtis
  • 17903, a novel human aminopeptidase and uses therefor
    Publication number: 20030096391
    Abstract: The invention provides isolated nucleic acids molecules, designated 17903 nucleic acid molecules, which encode novel aminopeptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 17903 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 17903 gene has been introduced or disrupted. The invention still further provides isolated 17903 proteins, fusion proteins, antigenic peptides and anti-17903 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 14, 2001
    Publication date: May 22, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Fong-Ying Tsai
  • Recombinant Carrier Molecule for Expression, Delivery and Purification of Target Polypeptides
    Publication number: 20120282288
    Abstract: Recombinant carrier molecules having amino acid sequences from thermostable enzymes and methods of use for expression, recovery and delivery of foreign sequences (peptides and polypeptides) produced in different systems (bacteria, yeast, DNA, cell cultures such as mammalian, plant, insect cell cultures, protoplast and whole plants in vitro or in vivo are provided. The recombinant carrier molecule using sequences from lichenase B (Lic B) were also made and used as part of carrier protein to express, recover and deliver a variety of target polypeptides of interest.
    Type: Application
    Filed: April 12, 2012
    Publication date: November 8, 2012
    Applicant: FRAUNHOFER USA, INC.
    Inventors: Vidadi Yusibov, Vadim Mett, Konstantin Musiychuk
  • 33521, a novel human guanine nucleotide exchange family member and uses thereof
    Publication number: 20020165145
    Abstract: The invention provides isolated nucleic acids molecules, designated 33521 nucleic acid molecules, which encode novel Rho GEF members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33521 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33521 gene has been introduced or disrupted. The invention still further provides isolated 33521 proteins, fusion proteins, antigenic peptides and anti-33521 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 25, 2001
    Publication date: November 7, 2002
    Inventor: Rachel E. Meyers
  • GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES
    Publication number: 20080274958
    Abstract: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries.
    Type: Application
    Filed: July 23, 2007
    Publication date: November 6, 2008
    Applicant: Neose Technologies, Inc.
    Inventor: Shawn DeFrees
  • Ligand activated transcriptional regulator proteins
    Patent number: 7442784
    Abstract: Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: October 28, 2008
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Carlos F. Barbas, III, Michael Joseph Kadan, Roger Beerli
  • 67108, a human phospholipid transporter family member and uses therefor
    Publication number: 20030003539
    Abstract: The invention provides isolated nucleic acids molecules, designated 67108 nucleic acid molecules, which encode novel phospholipid transporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 67108 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 67108 gene has been introduced or disrupted. The invention still further provides isolated 67108 proteins, fusion proteins, antigenic peptides and anti-67108 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: June 12, 2002
    Publication date: January 2, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Rory A.J. Curtis
  • GLYCOSYLATION OF PEPTIDES VIA O-LINKED GLYCOSYLATION SEQUENCES
    Publication number: 20080242607
    Abstract: The present invention provides sequon polypeptides with an amino acid sequence including one or more exogenous O-linked glycosylation sequence of the invention. In addition, the present invention provides methods of making polypeptide conjugates as well as methods of using such conjugates and their pharmaceutical compositions. The invention further provides libraries of sequon polypeptides, wherein each member of such library includes at least one exogenous O-linked glycosylation sequence of the invention. Also provided are methods of making and using such libraries.
    Type: Application
    Filed: July 23, 2007
    Publication date: October 2, 2008
    Applicant: Neose Technologies, Inc.
    Inventor: Shawn DeFrees
  • Single-chain polypeptides comprising troponin I N-terminal fragments and troponin C
    Patent number: 6475785
    Abstract: This invention relates to single-chain polypeptides and their genetic sequences comprising a human cardiac troponin I N-terminal fragment and troponin C. The N-terminal fragment may or may not have the intact N-terminus. The single-chain polypeptide may be expressed recombinantly, and a linker or spacer polypeptide or peptide may be interposed between the troponin sequences. The single-chain polypeptides have utility as controls or calibrators for troponin assays, for the purification of troponin subunits and as an antigen for the preparation of antibodies.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: November 5, 2002
    Assignee: Spectral Diagnostics, Inc.
    Inventors: Qinwei Shi, Shigui Liu, Mingfu Ling
  • Transgenic ungulate compositions and methods
    Patent number: 7071373
    Abstract: Transgenic ungulates and compositions and methods for making and using same, are provided. Central to the invention are porcine, bovine, ovine and caprine embryonic stem cell lines and methods for establishing them. Cells of such lines are transformed with exogenous genetic material of interest and then used to provide chimeric ungulates confirmed by genetic markers which have germ cells comprising the exogenous genetic material. The chimeric ungulates are bred to provide transgenic ungulates. The transgenic animals of the invention may show improved qualities and can be used to provide human proteins or peptide hormones or can be used as xenograft donors.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: July 4, 2006
    Assignee: The Board of Trustees of the University of Illinois
    Inventor: Matthew B. Wheeler
  • Ligand activated transcriptional regulator proteins
    Patent number: 7329728
    Abstract: Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: February 12, 2008
    Assignees: The Scripps Research Institute, Novartis AG
    Inventors: Carlos F. Barbas, III, Michael Joseph Kadan, Roger Beerli
  • 33449, a human protease family member and uses thereof
    Publication number: 20020115630
    Abstract: The invention provides isolated nucleic acids molecules, designated 33449 nucleic acid molecules, which encode novel protease or S26 signal peptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33449 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33449 gene has been introduced or disrupted. The invention still further provides isolated 33449 proteins, fusion proteins, antigenic peptides and anti-33449 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: January 14, 2002
    Publication date: August 22, 2002
    Inventors: Rachel E. Meyers, Peter J. Olandt
  • 33428, a novel human metalloprotease family member and uses thereof
    Publication number: 20020072490
    Abstract: The invention provides isolated nucleic acids molecules, designated 33428 nucleic acid molecules, which encode novel metalloprotease family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33428 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33428 gene has been introduced or disrupted. The invention still further provides isolated 33428 proteins, fusion proteins, antigenic peptides and anti-33428 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: May 15, 2001
    Publication date: June 13, 2002
    Inventors: Rosana Kapeller-Libermann, William James Cook, Inmaculada Silos-Santiago
  • Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
    Patent number: 5876712
    Abstract: Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 2, 1999
    Assignee: University of Washington
    Inventors: Martin A. Cheever, Mary L. Disis
  • Unique associated Kaposi's sarcoma virus sequences and uses thereof
    Patent number: 5801042
    Abstract: This invention provides an isolated DNA molecule which is at least 30 nucleotides in length and which uniquely defines a herpesvirus associated with Kaposi's sarcoma. This invention provides an isolated herpesvirus associated with Kaposi's sarcoma. This invention provides an antibody specific to the peptide. Antisense and triplex oligonucleotide molecules are also provided. This invention provides a method of vaccinating a subject for KS, prophylaxis, diagnosing or treating a subject with KS and detecting expression of a DNA virus associated with Kaposi's sarcoma in a cell.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: September 1, 1998
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Yuan Chang, Patrick S. Moore
  • Ubiqutin proteases
    Patent number: 7329529
    Abstract: The invention provides isolated nucleic acids molecules that encode novel ubiquitin protease polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the ubiquitin protease nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a ubiquitin protease sequence of the invention has been introduced or disrupted. The invention still further provides isolated ubiquitin protease proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: February 12, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rosana Kapeller-Libermann
  • 62112, a novel human dehydrogenase and uses thereof
    Publication number: 20020127680
    Abstract: The invention provides isolated nucleic acids molecules, designated DHDR-7 nucleic acid molecules, which encode novel human dehydrogenase molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing DHDR-7 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a DHDR-7 gene has been introduced or disrupted. The invention still further provides isolated DHDR-7 polypeptides, fusion polypeptides, antigenic peptides and anti-DHDR-7 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: August 31, 2001
    Publication date: September 12, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel Meyers, John Joseph Hunter